Kidney Disease & Nephrology Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease

This Phase III trial is testing elecoglipron, an oral medication, to see if it can slow down the loss of kidney function and reduce the risk of death in adults with chronic kidney disease. If successful, elecoglipron could offer a new treatment option for people living with this condition. The study plans to enroll 7,000 participants across multiple countries and is preparing to begin recruiting soon.

Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

This Phase III trial is evaluating spironolactone, a pill commonly used for heart conditions, in patients with end-stage kidney disease who require dialysis. The goal is to find out if spironolactone can lower the chances of death or hospital stays due to heart failure, a frequent complication in dialysis patients. More than 2,500 patients have been enrolled internationally, and the results may help improve treatment choices for people on dialysis.

Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease

This study explores the relationship between gut bacteria and chemical changes in the body in people with diabetic kidney disease. By better understanding these connections, researchers hope to identify new ways to prevent or slow down kidney damage caused by diabetes. The study involved over 500 participants in China and focused on non-invasive tests, which may make future monitoring easier for patients.

Real World Evidence Clinical Utility Study of KidneyIntelX

This study is examining how the KidneyIntelX test, which analyzes kidney health risk, affects treatment decisions in adults with type 2 diabetes and chronic kidney disease. Using this test could help doctors identify patients at higher risk earlier and tailor treatments to protect kidney function. The trial is currently recruiting participants in the United States and aims to provide real-world information on the test’s usefulness.

Prospective Decision Impact Trial of KidneyIntelX

This trial is also focused on the KidneyIntelX test in adults with type 2 diabetes and early-stage chronic kidney disease. It aims to show whether using this test helps doctors better predict kidney decline and make more personalized treatment decisions. The study is active but not recruiting, and results are expected to provide insights into managing early kidney disease more effectively.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.